2cureX AB (2CUREX) - Cash Flow Conversion Efficiency

Latest as of June 2025: 3.288x

Based on the latest financial reports, 2cureX AB (2CUREX) has a cash flow conversion efficiency ratio of 3.288x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr2.06 Million ≈ $221.47K USD) by net assets (Skr626.00K ≈ $67.37K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 2cureX AB net asset quality index to measure how much of total assets are equity-financed.

2cureX AB - Cash Flow Conversion Efficiency Trend (2015–2024)

This chart illustrates how 2cureX AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how aggressively does 2cureX AB reinvest cash to assess the company's total reinvestment commitment from operating cash flow.

2cureX AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of 2cureX AB ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Golden Sky Minerals Corp
V:AUEN
0.777x
Bluelinea SA
PA:ALBLU
-0.615x
Lakshmi Finance & Industrial Corporation Limited
NSE:LFIC
-0.054x
Trajano Iberia Socimi SA
MC:YTRA
0.005x
AquaBounty Technologies Inc
NASDAQ:AQB
0.480x
Exact Therapeutics AS
OL:EXTX
-0.697x
Pacte Novation
PA:MLPAC
N/A
Kanger International Bhd
KLSE:0170
-0.041x

Annual Cash Flow Conversion Efficiency for 2cureX AB (2015–2024)

The table below shows the annual cash flow conversion efficiency of 2cureX AB from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see 2cureX AB stock valuation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 Skr5.10 Million
≈ $548.73K
Skr-4.63 Million
≈ $-497.83K
-0.907x +64.90%
2023-12-31 Skr12.08 Million
≈ $1.30 Million
Skr-31.22 Million
≈ $-3.36 Million
-2.585x -297.53%
2022-12-31 Skr43.03 Million
≈ $4.63 Million
Skr-27.98 Million
≈ $-3.01 Million
-0.650x -162.37%
2021-12-31 Skr74.34 Million
≈ $8.00 Million
Skr-18.43 Million
≈ $-1.98 Million
-0.248x -24.76%
2020-12-31 Skr58.86 Million
≈ $6.33 Million
Skr-11.69 Million
≈ $-1.26 Million
-0.199x +29.07%
2019-12-31 Skr28.08 Million
≈ $3.02 Million
Skr-7.86 Million
≈ $-846.29K
-0.280x -431.76%
2018-12-31 Skr13.62 Million
≈ $1.47 Million
Skr1.15 Million
≈ $123.76K
0.084x +139.30%
2017-12-31 Skr20.24 Million
≈ $2.18 Million
Skr-4.35 Million
≈ $-467.91K
-0.215x -240.95%
2016-12-31 Skr7.91 Million
≈ $851.78K
Skr1.21 Million
≈ $129.84K
0.152x +160.87%
2015-12-31 Skr8.19 Million
≈ $881.25K
Skr-2.05 Million
≈ $-220.70K
-0.250x --

About 2cureX AB

ST:2CUREX Sweden Biotechnology
Market Cap
$4.67 Million
Skr43.38 Million SEK
Market Cap Rank
#28677 Global
#650 in Sweden
Share Price
Skr1.73
Change (1 day)
-0.12%
52-Week Range
Skr0.51 - Skr3.68
All Time High
Skr28.20
About

2cureX AB (publ) operates as a medical technology company in Europe. The company's principal product is IndiTreat, an IVD test for the treatment of cancer by establishing 3D copies of the patient's tumor and directly testing them against therapies. 2cureX AB (publ) was incorporated in 2006 and is based in Copenhagen, Denmark.